Substrate-Based Design of the First Class of Angiotensin-Converting Enzyme-Related Carboxypeptidase (ACE2) Inhibitors
Natalie A. Dales(Millennium Engineering and Integration (United States)), Michael A. Patane(IIT@MIT), Emily F. Calderwood(Millennium Engineering and Integration (United States)), Chad Vickers(Millennium Engineering and Integration (United States)), Michael Stewart(The University of Queensland), Alexandra E. Gould(Takeda (United States)), Virendar K. Kaushik(Broad Institute), Peter J. Tummino(Intarcia Therapeutics (United States)), Timothy D. Ocain(Millennium Engineering and Integration (United States)), James M. Gavin(Millennium Engineering and Integration (United States)), James A. Brown(University of Iowa Health Care), Paul Hales(Millennium Engineering and Integration (United States)), Charles A. Minor(Millennium Engineering and Integration (United States)), Bing Guan(Toshima Manufacturing (Japan))
Cited by 189
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k